NOTICE TO THE BAR

CIVIL CASE INFORMATION STATEMENT (CIVIL CIS) -- PAGE 1: ADDITION OF COVID-19 INDICATOR; PAGE 4: UPDATES TO TRACK IV CASE TYPES (MULTICOUNTY LITIGATION); AND TECHNICAL REVISIONS

This notice promulgates a number of revisions to the Civil Case Information Statement ("Civil CIS"), which is included in the Rules of Court as Appendix XII-B1. The attached version of the Civil CIS reflecting those revisions will be effective May 1, 2022.

The Supreme Court has approved the addition of a COVID-19 indicator on Page 1 of the Civil CIS, specifically a question asking whether the claim is related to COVID-19.

In addition, a number of amendments are being made to Page 4 of the Civil CIS to reflect new Multicounty Litigation case types as authorized by the Court, as follows:

- The addition of case type 635 involving the drug Tasigna pursuant to the Court's May 28, 2021 Order;
- The addition of case type 636 involving Strattice Hernia Mesh products pursuant to the Court's October 12, 2021 Order;
- The addition of case type 638 involving the drug Elmiron pursuant to the Court's December 7, 2021 Order; and
- The addition of case type 637 involving the drug Singulair pursuant to the Court's January 4, 2022 Order.

The updated Civil CIS also reflects the removal of several case types for the following now-concluded MCL designations: Risperdal/Seroquel/Zyprexa (case type 274); Levaquin (case type 286); Reglan (case type 289); AlloDerm Regenerative Tissue Matrix (case type 295); Mirena Contraceptive Device (case type 297); and Propecia (case type 623).

A number of technical edits are also reflected in the amended Civil CIS.

Questions concerning these changes to the Civil CIS may be directed to Melissa A. Czartoryski, Chief, Civil Court Programs, Civil Practice Division, Administrative Office of the Courts, Hughes Justice Complex, P.O. Box 981, Trenton, New Jersey 08625-0981; telephone 609-815-2900 ext. 54900; e-mail address: Melissa.Czartoryski@njcourts.gov.

Glenn A. Grant

Administrative Director of the Courts

Dated: April 19, 2022



New Jersey Judiciary Civil Practice Division

Civil Case Information Statement (CIS)

Use for initial Law Division Civil Part pleadings (not motions) under Rule 4:5-1. Pleading will be rejected for filing, under Rule 1:5-6(c), if information above the black bar is not completed, or attorney's signature is not affixed.

For Use by Clerk's Office Only					
	Charge/Check Number		Overpayment		Batch Number
□ charge □ cash		\$	\$		
Attorney/Pro Se Name	Tele _]	phone Num	ber	Co	ounty of Venue
Firm Name (if applicable)			Docket	Numb	er (when available)
Office Address - Street	City	7			State Zip
Document Type				Jury I □ Ye	Demand No
Name of Party (e.g., John Doe, Plaintiff) Ca	ption				
Case Type Number (See page 3 for listing)					
Are sexual abuse claims alleged?				Yes	□ No
Does this case involve claims related to COV.	ID-19	?		Yes	\square No
Is this a professional malpractice case?				Yes	□ No
If "Yes," see N.J.S.A. 2A:53A-27 and appregarding your obligation to file an affidav					
Related Cases Pending?				Yes	□ No
If "Yes," list docket numbers					
Do you anticipate adding any parties (arising transaction or occurrence)?	out of	f same		Yes	□ No
Name of defendant's primary insurance comp	any (if known)		None	□ Unknown

The Information Provided on This Form Cannot be Intro	duced in	to Evidence.
Case Characteristics for Purposes of Determining if Case is Approp	oriate for l	Mediation
Do parties have a current, past or recurrent relationship? If "Yes," is that relationship: □ Employer/Employee □ Friend/Neighbor □ Fami □ Other (explain)	□ Yes	☐ No ☐ Business
Does the statute governing this case provide for payment of fees by the losing party?	☐ Yes	□ No
Use this space to alert the court to any special case characteristics the management or accelerated disposition.	hat may w	varrant individual
Do you or your client need any disability accommodations? If yes, please identify the requested accommodation:	□ Yes	□ No
Will an interpreter be needed? If yes, for what language?	□ Yes	□ No
I certify that confidential personal identifiers have been redacted submitted to the court and will be redacted from all documents accordance with Rule 1:38-7(b). Attorney/Self-Represented Litigant Signature:		

Civil Case Information Statement (CIS)

Use for initial pleadings (not motions) under Rule 4:5-1

CASE TYPES

(Choose one and enter number of case type in appropriate space on page 1.)

Track I - 150 days discovery

- Name Change
- 175 Forfeiture
- 302 Tenancy
- Real Property (other than Tenancy, Contract, Condemnation, Complex Commercial or Construction)
- Book Account (debt collection matters only)
- 505 Other Insurance Claim (including declaratory judgment actions)
- 506 PIP Coverage
- 510 UM or UIM Claim (coverage issues only)
- 511 Action on Negotiable Instrument
- 512 Lemon Law
- 801 Summary Action
- 802 Open Public Records Act (summary action)
- 999 Other (briefly describe nature of action)

Track II - 300 days discovery

- 305 Construction
- 509 Employment (other than Conscientious Employees Protection Act (CEPA) or Law Against Discrimination (LAD))
- 599 Contract/Commercial Transaction
- 603N Auto Negligence Personal Injury (non-verbal threshold)
- 603Y Auto Negligence Personal Injury (verbal threshold)
- 605 Personal Injury
- Auto Negligence Property Damage
- 621 UM or UIM Claim (includes bodily injury)
- 699 Tort Other

Track III - 450 days discovery

- 005 Civil Rights
- 301 Condemnation
- Assault and Battery
- 604 Medical Malpractice
- 606 Product Liability
- 607 Professional Malpractice
- 608 Toxic Tort
- 609 Defamation
- Whistleblower / Conscientious Employee Protection Act (CEPA) Cases
- 617 Inverse Condemnation
- 618 Law Against Discrimination (LAD) Cases

Track	IV - Active Case Management by Individual Judge / 450 days discovery
156	Environmental/Environmental Coverage Litigation
303	Mt. Laurel
508	Complex Commercial
513	Complex Construction
514	Insurance Fraud
620	False Claims Act
701	Actions in Lieu of Prerogative Writs
Multio	county Litigation (Track IV)
271	Accutane/Isotretinoin
281	Bristol-Myers Squibb Environmental
282	Fosamax
285	Stryker Trident Hip Implants
291	Pelvic Mesh/Gynecare
292	Pelvic Mesh/Bard
293	DePuy ASR Hip Implant Litigation
296	Stryker Rejuvenate/ABG II Modular Hip Stem Components
299	Olmesartan Medoxomil Medications/Benicar
300	Talc-Based Body Powders
601	Asbestos
624	Stryker LFIT CoCr V40 Femoral Heads
625	Firefighter Hearing Loss Litigation
626	Abilify
627	Physiomesh Flexible Composite Mesh
628	Taxotere/Docetaxel
629	Zostavax
630	Proceed Mesh/Patch
631	Proton-Pump Inhibitors
632	HealthPlus Surgery Center
633	Prolene Hernia System Mesh
634	Allergan Biocell Textured Breast Implants
635	Tasigna
636	Strattice Hernia Mesh
637	Singulair
638	Elmiron
If y	ou believe this case requires a track other than that provided above, please indicate the
	reason on page 1, in the space under "Case Characteristics".
Please	e check off each applicable category
□ Pu₁	tative Class Action ☐ Title 59 ☐ Consumer Fraud